Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical Trial
- PMID: 27918762
- DOI: 10.1001/jamaoncol.2016.5202
Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical Trial
Abstract
Importance: To our knowledge, this is the first randomized clinical trial evaluating an alternating treatment regimen in an attempt to delay disease progression in clear cell renal cell carcinoma.
Objective: To test our hypothesis that an 8-week rotating treatment schedule with pazopanib and everolimus delays disease progression, exhibits more favorable toxic effects, and improves quality of life when compared with continuous treatment with pazopanib.
Design, setting, and participants: This was an open-label, randomized (1:1) study (ROPETAR trial). In total, 101 patients with treatment-naive progressive metastatic clear cell renal cell carcinoma were enrolled between September 2012 and April 2014 from 17 large peripheral or academic hospitals in The Netherlands and followed for at least one year.
Interventions: First-line treatment consisted of either an 8-week alternating treatment schedule of pazopanib 800 mg/d and everolimus 10 mg/d (rotating arm) or continuous pazopanib 800 mg/d (control arm) until progression. After progression, patients made a final rotation to either pazopanib or everolimus monotherapy (rotating arm) or initiated everolimus (control arm).
Main outcome and measures: The primary end point was survival until first progression or death. Secondary end points included time to second progression or death, toxic effects, and quality of life.
Results: A total of 52 patients were randomized to the rotating arm (median [range] age, 65 [44-87] years) and 49 patients to the control arm (median [range] age, 67 [38-82] years). Memorial Sloan Kettering Cancer Center risk category was favorable in 26% of patients, intermediate in 58%, and poor in 15%. Baseline characteristics and risk categories were well balanced between arms. One-year PFS1 for rotating treatment was 45% (95% CI, 33-60) and 32% (95% CI, 21-49) for pazopanib (control). Median time until first progression or death for rotating treatment was 7.4 months (95% CI, 5.6-18.4) and 9.4 months (95% CI, 6.6-11.9) for pazopanib (control) (P = .37). Mucositis, anorexia, and dizziness were more prevalent in the rotating arm during first-line treatment. No difference in quality of life was observed.
Conclusions and relevance: Rotating treatment did not result in prolonged progression-free-survival, fewer toxic effects, or improved quality of life. First-line treatment with a vascular endothelial growth factor inhibitor remains the optimal approach in metastatic clear cell renal cell carcinoma.
Trial registration: clinicaltrials.gov Identifier: NCT01408004.
Similar articles
-
A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302).BMC Cancer. 2024 Jul 25;23(Suppl 1):1253. doi: 10.1186/s12885-023-10971-7. BMC Cancer. 2024. PMID: 39054430 Free PMC article. Clinical Trial.
-
EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma.Ann Oncol. 2015 Jun;26(6):1118-1123. doi: 10.1093/annonc/mdv078. Epub 2015 Feb 20. Ann Oncol. 2015. PMID: 25701452 Clinical Trial.
-
First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial.Int J Cancer. 2021 Feb 15;148(4):950-960. doi: 10.1002/ijc.33238. Epub 2020 Aug 18. Int J Cancer. 2021. PMID: 32738823 Clinical Trial.
-
Posterior Reversible Encephalopathy Syndrome With Concurrent Nephrotic Syndrome in a Patient Treated With Pazopanib for Metastatic Renal Cell Carcinoma: Case Report and Review of the Literature.Clin Genitourin Cancer. 2017 Feb;15(1):e99-e103. doi: 10.1016/j.clgc.2016.08.005. Epub 2016 Aug 10. Clin Genitourin Cancer. 2017. PMID: 27601362 Review. No abstract available.
-
Pazopanib: in advanced renal cell carcinoma.BioDrugs. 2010 Oct 1;24(5):279-86. doi: 10.2165/11205480-000000000-00000. BioDrugs. 2010. PMID: 20649181 Review.
Cited by
-
A phase II study of alternating sunitinib and temsirolimus therapy in patients with metastatic renal cell carcinoma.Cancer Med. 2023 Jun;12(12):13100-13110. doi: 10.1002/cam4.5990. Epub 2023 May 6. Cancer Med. 2023. PMID: 37148554 Free PMC article. Clinical Trial.
-
First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis.Cochrane Database Syst Rev. 2023 May 4;5(5):CD013798. doi: 10.1002/14651858.CD013798.pub2. Cochrane Database Syst Rev. 2023. PMID: 37146227 Free PMC article. Review.
-
Comparing efficacy and safety of first-line treatment of metastatic renal cell carcinoma: A Bayesian network meta-regression analysis.Front Oncol. 2023 Feb 22;13:1072634. doi: 10.3389/fonc.2023.1072634. eCollection 2023. Front Oncol. 2023. PMID: 36910649 Free PMC article.
-
Playing the Devil's Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma? - ie Strategies to Revert Resistance to mTOR Inhibitors.Cancer Manag Res. 2021 Oct 4;13:7623-7636. doi: 10.2147/CMAR.S267220. eCollection 2021. Cancer Manag Res. 2021. PMID: 34675658 Free PMC article. Review.
-
Targeted therapy for metastatic renal cell carcinoma.Cochrane Database Syst Rev. 2020 Oct 14;10(10):CD012796. doi: 10.1002/14651858.CD012796.pub2. Cochrane Database Syst Rev. 2020. PMID: 33058158 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous